Stay updated on Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial page.

Latest updates to the Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check44 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on recurrent glioblastoma, while a new version number has been added.SummaryDifference7%
- Check51 days agoChange DetectedThe page has been updated to reflect new dates and timeframes related to randomization and tumor progression, with the removal of outdated dates and timeframes.SummaryDifference1%
- Check58 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check87 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
Stay in the know with updates to Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial page.